MARKET

GDTC

GDTC

CytoMed Therapeutics Ltd
NASDAQ
2.220
-0.080
-3.47%
Closed 15:38 05/09 EDT
OPEN
2.260
PREV CLOSE
2.300
HIGH
2.290
LOW
2.210
VOLUME
11.39K
TURNOVER
0
52 WEEK HIGH
4.050
52 WEEK LOW
1.200
MARKET CAP
25.62M
P/E (TTM)
-11.3386
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GDTC last week (0505-0509)?
Weekly Report · 1h ago
CytoMed Therapeutics Reports 2024 Financial Results and Clinical Progress
TipRanks · 5d ago
Weekly Report: what happened at GDTC last week (0428-0502)?
Weekly Report · 05/05 09:35
CytoMed Therapeutics reports FY results
Seeking Alpha · 04/29 14:10
CytoMed Therapeutics Announces 2024 Financial Results and Clinical Advances
TipRanks · 04/28 21:28
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
Barchart · 04/28 15:05
Weekly Report: what happened at GDTC last week (0421-0425)?
Weekly Report · 04/28 09:37
Weekly Report: what happened at GDTC last week (0414-0418)?
Weekly Report · 04/21 09:37
More
About GDTC
More
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.
Recently
Symbol
Price
%Change

Webull offers CytoMed Therapeutics Ltd stock information, including NASDAQ: GDTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GDTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GDTC stock methods without spending real money on the virtual paper trading platform.